Italy · Delayed Price · Currency is EUR Cytokinetics Company Description
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States.
The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.
It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction.
In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials.
Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 1997 |
| Industry | Pharmaceutical Preparations |
| Employees | 673 |
| CEO | Robert Blum |
Contact Details
Address: 350 Oyster Point Boulevard South San Francisco, California 94080 United States | |
| Phone | 650 624 3000 |
| Website | cytokinetics.com |
Stock Details
| Ticker Symbol | 1CYTK |
| Exchange | Borsa Italiana |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert Blum | Chief Executive Officer |
| Sung Lee | Chief Financial Officer |
| Jeff Lotz | Chief Operating Officer |